Rady Johnson - Pfizer President

PFIZ34
  

BRL 66.77  0.71  1.07%   

  President
Mr. Rady A. Johnson, II, is the Executive Vice President, Chief Compliance and Risk Officer of Pfizer Inc.. Mr. Johnson is Senior Vice President and Associate General Counsel from October 2006 until December 2013.
Age: 56  President Since 2013      
212 733 2323  https://www.pfizer.com

Pfizer Management Efficiency

Pfizer Inc has return on total asset (ROA) of 0.1332 % which means that it generated profit of $0.1332 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 0.3551 %, meaning that it generated $0.3551 on every $100 dollars invested by stockholders. Pfizer management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 36.2 B in total debt with debt to equity ratio (D/E) of 0.44, which is about average as compared to similar companies. Pfizer Inc has a current ratio of 1.37, which is within standard range for the sector. Debt can assist Pfizer until it has trouble settling it off, either with new capital or with free cash flow. So, Pfizer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pfizer Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pfizer to invest in growth at high rates of return. When we think about Pfizer's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 10 records

PRESIDENT Since

Jonathan WeissWells Fargo
2017
James StrotherWells Fargo
2011
Richard LevyWells Fargo
2007
Hope HardisonWells Fargo
2015
Franklin CodelWells Fargo
2016
Mary MackWells Fargo
2017
C ParkerWells Fargo
2019
Kevin RheinWells Fargo
2011
Michael LoughlinWells Fargo
2011
John RaineyPayPal Holdings
2018
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. PFIZER DRN operates under Drug ManufacturersGeneral classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 79000 people. Pfizer Inc (PFIZ34) is traded on Sao Paolo Exchange in Brazil and employs 79,000 people.

Pfizer Inc Leadership Team

Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President of Global Established Pharma Bus.
Jennifer Damico, Controller VP
Frank DAmelio, CFO and Executive VP of Bus. Operations
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Director
James Smith, Director
Christopher CFA, VP Officer
Dennis Ausiello, Independent Director
Mikael Dolsten, President - Worldwide Research and Development
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President CTO and Digital Officer
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
David Denton, Chief VP
Alexander Mackenzie, Executive Vice President Chief Development Officer
DVM DVM, Chairman CEO
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Executive Vice President - Corporate Affairs
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Executive Vice President Chief Compliance and Risk Officer
Mikael MD, Dev Research
Dan Littman, Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President - Pfizer Essential Health
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Pfizer Preferred Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right preferred stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Pfizer Preferred Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.